2026 ICD-10-CM Diagnosis Code T45.615SAdverse effect of thrombolytic drugs, sequela
T45.615S is a billable ICD-10-CM diagnosis code for adverse effect of thrombolytic drugs, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T45.615S.
Present on Admission (POA)Billing
T45.615S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Adverse reaction caused by tissue plasminogen activator
- Adverse reaction to fibrinolytic drugs
- Adverse reaction to reteplase
- Adverse reaction to tenecteplase
- Alteplase adverse reaction
- Anistreplase adverse reaction
- Drug-induced fibrinolytic disorder
- Fibrinolytic disorder caused by tissue plasminogen activator
- Fibrinolytic disorder caused by urokinase
- Hemorrhage after administration of thrombolytic agent
- Intracranial hemorrhage following administration of thrombolytic agent
- Streptokinase adverse reaction
- Streptokinase streptodornase adverse reaction
- Urokinase adverse reaction
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified (T45). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Anistreplase
an acylated inactive complex of streptokinase and human lysine-plasminogen. after injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. its half-life is about 90 minutes compared to 5 minutes for tpa; (tissue plasminogen activator); 16 minutes for urokinase-type plasminogen activator and 23 minutes for streptokinase. if treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. bleeding complications are similar to other thrombolytic agents.Streptodornase and Streptokinase
a mixture of the enzymes (streptokinase and streptodornase) produced by hemolytic streptococci. it is used topically on surface lesions and by instillation in closed body cavities to remove clotted blood or fibrinous or purulent accumulations. it is also used as a skin test antigen in evaluating generalized cell-mediated immunodeficiency. (dorland, 27th ed) ec 3.-.Streptokinase
streptococcal fibrinolysin . an enzyme produced by hemolytic streptococci. it hydrolyzes amide linkages and serves as an activator of plasminogen. it is used in thrombolytic therapy and is used also in mixtures with streptodornase (streptodornase and streptokinase). ec 3.4.-.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
| Substance | Accidental | Self-harm | Assault | Undetermined | Adverse Effect | Underdosing |
|---|---|---|---|---|---|---|
| Alteplase | T45.611 | T45.612 | T45.613 | T45.614 | T45.615 | T45.616 |
| Anistreplase | T45.611 | T45.612 | T45.613 | T45.614 | T45.615 | T45.616 |
| Fibrinolytic drug | T45.611 | T45.612 | T45.613 | T45.614 | T45.615 | T45.616 |
| Plasminogen (tissue) activator | T45.611 | T45.612 | T45.613 | T45.614 | T45.615 | T45.616 |
| Rt-PA | T45.611 | T45.612 | T45.613 | T45.614 | T45.615 | T45.616 |
| Streptokinase | T45.611 | T45.612 | T45.613 | T45.614 | T45.615 | T45.616 |
| Thrombolysin | T45.611 | T45.612 | T45.613 | T45.614 | T45.615 | T45.616 |
| Urokinase | T45.611 | T45.612 | T45.613 | T45.614 | T45.615 | T45.616 |
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T45.615S to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T45.615SOverview
Is T45.615S (Adverse effect of thrombolytic drugs) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of thrombolytic drugs, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character S in T45.615S mean?
The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of thrombolytic drugs itself has resolved, not the original event.
What MS-DRG does T45.615S group to?
On inpatient claims, adverse effect of thrombolytic drugs, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T45.615S be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of thrombolytic drugs, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Is T45.615S exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of thrombolytic drugs, sequela on inpatient claims.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
